← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Talus Bioscience, Inc.
Seattle, WA
$5,394,162
Total funding
6
Grants
Funding over time
peak $1.8M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,138,331 · 5
NSF$255,831 · 1
By mechanism
R44$3,951,023 · 2
R43$732,308 · 2
R42$455,000 · 1
—$255,831 · 1
Investigators at Talus Bioscience, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer$1,000,000
R44 · FY2023 · CA
Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer$1,000,000
R44 · FY2024 · CA
Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors$821,779
R44 · FY2024 · TR
Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors$821,779
R44 · FY2025 · TR
Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer$455,000
R42 · FY2022 · CA
Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins$398,441
R43 · FY2023 · GM
Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding$333,867
R43 · FY2022 · TR
Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors$307,465
R44 · FY2023 · TR
SBIR Phase I: Simultaneous In situ Pharmacological Profiling of Gene Regulatory Proteins (GRPs) for Cancer Therapy$255,831
· FY2021 · TIP